CR3 News Magazine 2019: November Issue - WHY Only $14 Million? - Page 45

https://www.epa.gov/radon/radon-schools

Clinical Trials

NCI funds and oversees both early- and late-phase clinical trials to develop new treatments and improve patient care. Trials are available for both non-small cell lung cancer prevention, screening, and treatment, and small cell lung cancer prevention, screening, and treatment.

Lung Cancer Research Results

The following are some of our latest news articles on lung cancer research:

Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene

FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type

Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans

Eliminating Racial Disparities in Lung Cancer Treatment

Risks of Follow-Up Procedures after Lung Cancer Screening

Atezolizumab Approved for Lung Cancer Initial Treatment

View the full list of Lung Cancer Research Results and Study Updates.

Posted: May 2, 2019

###

Continued .....

Advances in Lung Cancer Research

© Citizens for Radioactive Radon Reduction 2017 All rights reserved. Publications of the Citizens for Radioactive Radon Reduction can be obtained from Citizens for Radioactive Radon Reduction, 618 Evansville Ave. Waterloo, IL 62298 (tel.: (618) 830-4660; e-mail: info@citizens4radonreduction.org). Requests for permission to reproduce or translate CR3 News Magazine publications – whether for sale or for noncommercial distribution – should be addressed to the CR3 News Magazine Publisher, at the above address . The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Citizens for Radioactive Radon Reduction concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the Citizens for Radioactive Radon Reduction in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the Citizens for Radioactive Radon Reduction to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the Citizens for Radioactive Radon Reduction be liable for damages arising from its use. Printed in the United States of America.

45